Deerfield Dakota Holdings

Deerfield Dakota Holdings is a private holding company and investment vehicle managed by Deerfield Management, a leading healthcare-focused investment firm. The entity was primarily established to facilitate the acquisition and subsequent restructuring of Melinta Therapeutics, which was completed in April 2020 following Melinta's Chapter 11 bankruptcy proceedings. Through its ownership of Melinta, Deerfield Dakota Holdings oversees a specialized portfolio of commercial-stage anti-infective therapies designed for use in hospital and acute care settings. The company's product lineup includes several FDA-approved antibiotics, such as Baxdela, Vabomere, Orbactiv, and Kimyrsa, which target serious bacterial infections including ABSSSI and cUTI. Deerfield Dakota Holdings provides the strategic leadership and financial resources necessary to support Melinta's mission of addressing the global threat of antimicrobial resistance. The company operates as a private entity, focusing on the commercialization and life-cycle management of its infectious disease franchise.